THE EFFECTS OF ENDOTHELIN-A RECEPTOR BLOCKADE DURING THE PROGRESSION OF PACING-INDUCED CONGESTIVE-HEART-FAILURE

Citation
D. Saad et al., THE EFFECTS OF ENDOTHELIN-A RECEPTOR BLOCKADE DURING THE PROGRESSION OF PACING-INDUCED CONGESTIVE-HEART-FAILURE, Journal of the American College of Cardiology, 32(6), 1998, pp. 1779-1786
Citations number
32
Categorie Soggetti
Cardiac & Cardiovascular System
ISSN journal
07351097
Volume
32
Issue
6
Year of publication
1998
Pages
1779 - 1786
Database
ISI
SICI code
0735-1097(1998)32:6<1779:TEOERB>2.0.ZU;2-X
Abstract
Objectives. We sought to identify the effects of endothelin (ET) subty pe-A (ETA) receptor blockade during the development of congestive hear t failure (CHF) on left ventricle (LV) function and contractility. Bac kground. Congested heart failure causes increased plasma levels of ET and ETA receptor activation. Methods. Yorkshire pigs were assigned to four groups: 1) CHF: 240 beats/min for 3 weeks; n = 7; 2) CHF/ETA-High Dose: paced for 2 weeks then ETA receptor blockade (BMS 193884, 50 mg /kg, b.i.d.) for the last week of pacing; n = 6; 3) CHF/ETA-Low Dose: pacing for 2 weeks then ETA receptor blockade (BMS 193884, 12.5 mg/kg, b.i.d.) for the last week, n = 6; and 4) Control: n = 8. Results. Lef t ventricle fractional shortening decreased with CHF compared with con trol (12 +/- 1 vs. 39 a 1%, p < 0.05) and increased in the CHF/ETA Hig h and Low Dose groups (23 +/- 3 and 25 +/- 1%, p < 0.05). The LV peak wall stress and wall force increased approximately twofold with CHF an d remained increased with ETA receptor blockade. With CHF, systemic va scular resistance increased by 120%, was normalized in the CHF/ETA Hig h Dose group, and fell by 43% from CHF values in the Low Dose group (p < 0.05). Plasma catecholamines increased fourfold in the CHF group an d were reduced by 48% in both CHF/ETA blockade groups. The LV myocyte velocity of shortening was reduced with CHF (32 3 vs. 54 +/- 3 mu m/s, p < 0.05), was higher in the CHF/ETA High Dose group (39 +/- 1 mu m/s , p < 0.05), and was similar to CHF values in the Low Dose group. Conc lusions. ETA receptor activation may contribute to the progression of LV dysfunction with CHF. (J Am Cell Cardiol 1998;32:1779-86) (C) 1998 by the American College of Cardiology.